Immunodiagnostic assay for cancer diseases in dogs - product customization and clinical studies

Important results from the project

** Denna text är maskinöversatt ** The goals in the development of the immune test to determine the risk of cancer in dogs have largely been achieved, but the final completion and approval will be possible next year.

Expected long term effects

** Denna text är maskinöversatt ** The project will not be able to be completed in 2022 but with a high probability in 2023.

Approach and implementation

** Denna text är maskinöversatt ** All steps have been optimized, and the first important steps have delivered approved industrial microtiter plates. Other steps have been optimized and planning of the implementation of the last two steps is underway with a commercial partner in Sweden.